ICON PLC
NASDAQ:ICLR
Intrinsic Value
ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. [ Read More ]
The intrinsic value of one ICLR stock under the Base Case scenario is 322.19 USD. Compared to the current market price of 293.14 USD, ICON PLC is Undervalued by 9%.
Valuation Backtest
ICON PLC
Run backtest to discover the historical profit from buying and selling ICLR stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
ICON PLC
Current Assets | 3.4B |
Cash & Short-Term Investments | 380.1m |
Receivables | 2.9B |
Other Current Assets | 132.1m |
Non-Current Assets | 13.6B |
Long-Term Investments | 46.8m |
PP&E | 501.5m |
Intangibles | 12.9B |
Other Non-Current Assets | 152.1m |
Current Liabilities | 2.8B |
Accounts Payable | 131.6m |
Accrued Liabilities | 36.4m |
Other Current Liabilities | 2.7B |
Non-Current Liabilities | 4.9B |
Long-Term Debt | 3.7B |
Other Non-Current Liabilities | 1.3B |
Earnings Waterfall
ICON PLC
Revenue
|
8.1B
USD
|
Cost of Revenue
|
-5.7B
USD
|
Gross Profit
|
2.4B
USD
|
Operating Expenses
|
-1.4B
USD
|
Operating Income
|
1B
USD
|
Other Expenses
|
-433.4m
USD
|
Net Income
|
612.3m
USD
|
Free Cash Flow Analysis
ICON PLC
What is Free Cash Flow?
ICLR Profitability Score
Profitability Due Diligence
ICON PLC's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
Score
ICON PLC's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
ICLR Solvency Score
Solvency Due Diligence
ICON PLC's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Score
ICON PLC's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ICLR Price Targets Summary
ICON PLC
According to Wall Street analysts, the average 1-year price target for ICLR is 358.33 USD with a low forecast of 287.85 USD and a high forecast of 404.25 USD.
Shareholder Return
ICLR Price
ICON PLC
Average Annual Return | 15.59% |
Standard Deviation of Annual Returns | 37.45% |
Max Drawdown | -35% |
Market Capitalization | 24.2B USD |
Shares Outstanding | 83 112 800 |
Percentage of Shares Shorted | 1.7% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. The company is headquartered in Dublin, Dublin and currently employs 38,330 full-time employees. The firm is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. The firm specialises in the strategic development, management and analysis of programs that support clinical development from compound selection to Phase I-IV clinical studies. Its services include clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics and laboratory services. The company conducts various laboratory tests on the patient's blood, urine and other bodily fluids at appropriate intervals during the trial. The firm offers clinical development services, including investigator recruitment, patient registries, outcomes research, clinical data management, immunoassay development and others.
Contact
IPO
Employees
Officers
The intrinsic value of one ICLR stock under the Base Case scenario is 322.19 USD.
Compared to the current market price of 293.14 USD, ICON PLC is Undervalued by 9%.